1. Reversing effect of Lupeol on vasculogenic mimicry in murine melanoma progression.
- Author
-
Bhattacharyya, Sayantan, Mitra, Debarpan, Ray, Sudipta, Biswas, Nirjhar, Banerjee, Samir, Majumder, Biswanath, Mustafi, Saunak Mitra, and Murmu, Nabendu
- Subjects
- *
VASCULOGENIC mimicry , *PATHOLOGIC neovascularization , *MICROCIRCULATION , *CANCER stem cells , *CANCER invasiveness - Abstract
Abstract Vasculogenic mimicry, an endothelia-independent tumor microcirculation has been found in various cancers and is thought to be achieved by cancer stem like cells. Dacarbazine resistance is one of the most common features of melanoma and recent studies suggest that the mode of resistance is closely related to the formation of vasculogenic mimicry. In our work, we examined the anticancer effect of Lupeol, a novel phytochemical with Dacarbazine in vivo and in vitro. Results demonstrated adequate cytotoxicity followed by down regulation of CD 133 expression in Lupeol treated B16-F10 cell line. In solid tumor model the drug also inhibited vasculogenic mimicry along with angiogenesis by altering both the cancer stem cell as well as the endothelial progenitor cell population. Lupeol hindered the maturation of bone marrow derived endothelial progenitors and thus, retarded the formation of rudimentary tumor microvessels. Notably, Dacarbazine treatment demonstrated unresponsiveness to B16-F10 cells in both in vivo and in vitro model via upregulation of CD 133 expression and increased formation of vasculogenic mimicry tubes. Together, these data indicate that Lupeol alone can become a proficient agent in treating melanoma, inhibiting vasculogenic mimicry and might play a significant role in subduing Dacarbazine induced drug resistance. Highlights • Lupeol shows excellent cytotoxicity against B16-F10 melanoma cancer cells in vivo and in vitro. • Lupeol overcomes Dacarbazine resistance by inhibiting vasculogenic mimicry. • Lupeol also inhibits tumor angiogenesis by inhibiting the maturation and homing of Endothelial Progenitor Cells (EPC). [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF